RT Journal Article SR Electronic T1 Epidemiologic Profile of Erectile Dysfunction in Patients with Systemic Lupus Erythematosus: The Latin American Landscape JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 397 OP 404 DO 10.3899/jrheum.180292 VO 46 IS 4 A1 Javier Merayo-Chalico A1 Ana Barrera-Vargas A1 Sandra Morales-Padilla A1 Roberto Reyna-De la Garza A1 Ricardo Vázquez-Rodríguez A1 Jonathan Campos-Guzmán A1 Jorge Alcocer-Varela A1 Mariano Sotomayor A1 Carlos Abud-Mendoza A1 Marco Martínez-Martínez A1 Iris Colunga-Pedraza A1 Christian Uriarte-Hernández A1 Roberto Acosta-Hernández A1 Daniel Fajardo A1 Conrado García-García A1 Diana Padilla-Ortíz A1 Diana Gómez-Martín YR 2019 UL http://www.jrheum.org/content/46/4/397.abstract AB Objective. The aim of this study was to describe the prevalence of erectile dysfunction (ED), as well as associated demographic and clinical features, in men with systemic lupus erythematosus (SLE), by means of a systematic, standardized evaluation.Methods. We performed a transversal study in 8 tertiary care centers in Latin America. We included male patients ≥ 16 years who fulfilled ≥ 4 American College of Rheumatology criteria for SLE and had regular sexual activity, and evaluated them with the International Index of Erectile Function-5 questionnaire. Relevant demographic, clinical, and serological characteristics were recorded. We included 2 control groups: the first was made up of healthy men and the second of men with autoimmune diseases other than SLE (non-SLE group).Results. We included 590 subjects (174 SLE, 55 non-SLE, and 361 healthy controls). The prevalence of ED in the SLE group was 69%. Mean age in that group was 36.3 ± 1.03 years. Among SLE patients with and without ED, these factors were significantly different: the presence of persistent lymphopenia (p = 0.006), prednisone dose (9.3 ± 1.2 vs 5.3 ± 1.3 mg, p = 0.026), and the Systemic Lupus International Collaborating Clinics damage score (1.25 ± 0.14 vs 0.8 ± 0.16 points, p = 0.042). Independent risk factors for ED in patients with SLE were persistent lymphopenia (OR 2.79, 95% CI 1.37–5.70, p = 0.001) and corticosteroid use in the previous year (OR 2.15, 95% CI 1.37–3.37, p = 0.001).Conclusion. Regardless of comorbidities, treatment (excluding steroids), and type of disease activity, patients with SLE have a high prevalence of ED, especially considering that most patients are young. Recent corticosteroid use and persistent lymphopenia, which could be related to endothelial dysfunction, are risk factors for this complication in men with SLE.